Shehan Dissanayake is the CEO of Tavistock Life Sciences. He oversees all of TLS's operations and portfolio companies, including its investments in Eidogen, CovX, and Kalypsys. Prior to joining TLS, Shehan served as Partner in Charge of Strategy and Business Planning for Andersen's Global Tax, Human Resource, and Legal operating unit. Shehan received his BA in biology and chemistry at Skidmore College and a PhD in cell physiology from The University of Chicago. Shehan is a native of Sri Lanka and an avid footballer and fan.